Skip to main content
Premium Trial:

Request an Annual Quote

Mesa Biotech Point-of-Care Testing Platform Garners CE Mark

NEW YORK (GenomeWeb) — Mesa Biotech said today that its PCR testing platform for point-of-care infectious disease testing has obtained CE marking in the EU.

The first available test in the EU market will be the company's Flu A/Flu B test.

The Accula System is a palm-sized device that accepts disposable test cassettes. The cassette contains all necessary reagents for lysis and nucleic acid amplification. The system does not require as much power as a standard thermal cycler, and can be run using a rechargeable battery pack. Readout is performed on a lateral flow strip, with results available in about 30 minutes.

"The introduction of the Accula System and its Flu A/Flu B test as our first PCR assay in the European market is an important validation of our platform and a critical strategic milestone for Mesa Biotech," Mesa CEO and Founder Hong Cai said in a statement. "Our proprietary assay design enables rapid development of a portfolio of cassettes to test for human, agricultural, food pathogens, or genetic disease targets."

In December, Mesa announced a distribution deal with Sekisui Diagnostics, which will exclusively distribute the Accula system and flu test in the US and Canada pending regulatory clearance in those countries.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.